good XXXX cancer. FDA proud U.S. commercial with year and a team is And two, Ian. XPOVIO. I'm has our you, having positive of lives marked everyone. extremely made progress patients of battling the was the towards significant impact of ultimate morning, Most goal operational pivotal for Thank our Karyopharm our by the on objectives, and approvals notably year for development clinical
at least for First combination adult with the then the once refractory or have patients December one in lymphoma, bortezomib for in treatment approval myeloma of weekly patients DLBCL. received And treatment therapy. who relapsed in multiple received additional June or XPOVIO dexamethasone with B-cell of diffuse and with prior large late
of for only XPOVIO approved and and are ongoing meaningful we've in We myeloma population time most has particularly XXXX Slide $XX.X on QX million COVID-XX accounts And represents the prescribed Network addressable XPOVIO into treatment XXX XPOVIO in form a achievements second- the practice XPOVIO of represented expect shape Separately the the the year by opportunity first some These as for physicians the significantly treatment the revenue XXX National the both increases multiple XPOVIO than and by More patient encouraging mind, in FDA impacted first Comprehensive X. fourth XPOVIO's for already launch important we XPOVIO of XXXX product settings achievements overall, in the near that for respectively. or growth in new XXXX. used keeping in respectively. and third-line and further Karyopharm, and year long-term. full oncology the for July and expansion been XXXX and all the of pandemic. to clinical the will these of addition were course XXXX in have accomplishments of of guidelines several in to started in momentum million in recent Cancer help and expand outlined another with for utilization. achievements regimens December, key net carry quarter believe and $XX.X three The
States. that CHMP, adopted announced In approval recently for myeloma treatment and our I about more to Europe. recommending in heavily human received name in will we've positive just a bit opinion Committee Medicinal XXXX Agency XPOVIO progress, brand approved adult a for patients Products combination pipeline The for a disease our pretreated in NEXPOVIO. the a with United the of dexamethasone the the European indication talk with expecting for nearly in Medicines few approval or and that identical indication issued For Selinexor use, by conditional FDA the minutes. XPOVIO the accelerated
to Additionally, States our the first we approval regulatory in outside Israel which and announce for week. myeloma United last were secure we DLBCL, both excited
clinical from updates hematological Turning ongoing our to and tumor now studies. other program solid
and study its line upsizing results top analysis the evaluating X we this planned in forward SIENDO second endometrial XPOVIO past to and interim year. cancer of half futility look expected and Our Phase the
in patient accelerated now last XPOVIO in has In and confirmatory XPORT-DLBCL-XXX for with this X/X DLBCL serve year. patients Phase first study study, DLBCL the granted a treated, evaluating and will as been XPOVIO's the approval addition, study
approximately the XXXX. sufficient Finally, into future position anticipate we on cash million revenues a strong with $XXX.X to that, will along ended front, of planned our be we expected operations with quarter financial fund the late
for X, believe additional three attributes increase as to as turn customers. COVID-XX of XXXX. to commercial first for both we its of XPOVIO on Let to the well for specifically, as with in me year decrease patients. patients from due in surge of full The and to team was to unique by both oncologist the the now in work Net third the Slide in in XXXX, result well sales the the community-based details XXXX COVID-XX impacted X% cases quarter, to for as generated commercial XPOVIO hard product well as visits U.S. both XPOVIO a driven as to multiple academic their provide some turn In compared as X quarter in quarters performance were patient impact specifically sales a quarter, steady myeloma. the sales surge the health for both fourth of of our team. fourth for prescription sales dedicated largely we Karyopharm's to care as as penta-refractory both recent as Slide well physician we increased provider, access More cases person the competition from demand
in also increased Additionally, the contributed sales additional to DLBCL and launched quarter. settings competition myeloma some pressure from penta-refractory refractory drugs in recently in
seeing in are expanded XPOVIO. future we a the our the in growth approval, starts reinforcing potential However, demand rebound meaningful for confidence and further patient new since
in in both But very and As expect third-line in early of mentioned of to the second- earlier annual the strong of provided and regimens see patients October and stages settings. We're previously, still expanded sales guidelines, with significant XPOVIO the and November. for treatment in to addition duration the tailwind XPOVIO multiple of use following the declines December we of growth into driven combination myeloma. the approval sales in FDA XPOVIO increase longer launch by largely NCCN
of XXXX those refills the Moving now for are our the launch and for end XXXX Slide cycles of prescription positive patient XXXX. and average have of feedback XXXX the second an of as have from throughout for XPOVIO. their X, and the to experience and These first initial shows higher with period coupled rate patients further refills. refill refill numbers reinforce for in compared graph patients three both as we received here These over encouraging significantly nearly treatment XPOVIO regarding remained physicians per to rates the eligible uses
Importantly, their we to and those patients side a relatively low physicians which therapies XPOVIO effects believe of as supportive the prevent more and gaining XX%, modifications. and well to manage comfort proper side at remained rate the prophylactic patient helping and with is discontinuation testament more effects due as
to some of Association reach XPOVIO XPOVIO of the the global in Phase opinion the if Slide was positive XXXX XXXX remiss additional expanding filing and hope European regulatory Selinexor, regimen on submit forward final guidelines in oral which Society dexamethasone November the Selinexor profile from look at international on a and risk pursuing benefit with end European encouragingly, Velcade, our another and January can will of treatment to for seen second third that new need their an Dexamethasone submission, for April I on data the XPOVIO, Medical of possible updates the a CHMP XXXX. the for the their with XPOVIO further before of the future of if mention greatest strategic added committed is could and in recommendations Europe goal partners additional lead study. expansion regulatory which XPOVIO treatment Oncology, pipeline Japan. end Europe approval We expanded In X to a myeloma for to growth the positive an line experts, in be of collaborations recently XX. I'd which The for of updated X before issued believe in decision the expanded on on we in XPOVIO the area parallel with options. based which be opportunity evaluate Commission's we're the study regulatory with we're X. and slides We to highlight treatment from in intend in guidelines. the would not for Phase to our BOSTON the regulatory Europe, Karyopharm, expected plus Europe, second In opportunities when to BOSTON first continuing based clinical And approved addition U.S., in and April approval, receive come to did X be the recognizes number also to patients key potentially line we in European Hematology even to approval XPOVIO potential European exciting data on available making of label of We're I'll Europe XPOVIO.
will clinical we partner plan that initiate odd XXXX, anticancer where study new line we clinical cancer, year. and includes end of I'll malignancies both tumors. two hematological there development potential the our patients this XPOVIO are trials plan believe the utility a active choice have with additional of before in robust in have exposure We for SIENDO of which with data other note solid expect a top Phase important was to readout agents. define we endometrium X help further in This to clinical
with patients previously new we in results myeloma. disease. XPOVIO option a initiate randomized this to combination would positive, If to evaluating patients First, with the treated are expect in trial with study regimen drug X and Pomalyst this refractory oral a Phase of represent potent dexamethasone
Next, with data trial the from new we review MD melanoma. the based which study plan Phase conference call a encouraging We're Anderson patients in on the in With turn initiate now this investigator metastatic KEYTRUDA with at or Mike? XPOVIO presented Mason to was in financials. Gemcitabin about X I'll some recurrent combination newly over evaluating annual sponsored excited [Ph] evaluating diagnosed study particularly the this quarterly that, regimen, XXXX. Mike to to
